A total of 108 college women with acute urinary tract infections were treated for 10 days with either 500 mg of cefprozil (BMY-28100-03-800) once a day (n = 72) or 250 mg of cefaclor three times a day (n = 36). Clinical and bacterial cure rates at 1 week posttherapy were 94 and 93%, respectively, for the cefprozil group and 94 and 94%, respectively, for the cefaclor group (P, not significant). Both cefprozil and cefaclor were safe and effective.
within 3 to 5 days of initiation and at 5 to 9 days and 4 to 6 weeks posttherapy. During therapy, patients used diaries to record the times at which medication was taken and the times of resolution of symptoms. Clinical and bacteriologic responses were classified, as described previously (15) . Safety laboratory tests were performed prior to therapy, during days 3 to 5 of therapy, and 5 to 9 days posttherapy. Adverse events were monitored and recorded.
The life table method, the Fisher exact test, and chisquare analysis were used to compare treatment groups (6, 8, 23) . The mean ages of patients in the cefprozil and cefaclor groups were 22 + 4 and 22 ± 3 years, respectively. All patients had dysuria, frequency, urgency, and suprapubic pain. A total of 22% of the cefprozil patients and 25% of the cefaclor patients had costovertebral angle tenderness. The mean duration of symptoms before therapy was 4.8 ± 6 days in the cefprozil group and 4.3 ± 4 days in the cefaclor group. Of 109 pretherapy pathogens (one cefaclor patient had two pathogens), 108 (99%) were susceptible to cefprozil and 100 (92%) were susceptible to cephalothin (P = 0.024) ( Table 1) . In vitro susceptibility results were also in agreement with those of previous reports (5, 11, 17, 20, 24 (Table 2 ). There was no significant difference between the results of the two groups. These results were comparable to those of previous reports (7, 12, 15, 16, 18, 27 of periurethral and vaginal sites decreased in both the cefprozil (P = 0.003 and P = 0.001, respectively) and the cefaclor (P = 0.029, and P = 0.047, respectively) groups. No significant change occurred in the frequency of E. coli in the rectal flora posttherapy for either group. In the cefprozil group, the frequency of E. coli resistant to cephalothin increased in the vaginal flora (P = 0.044) and the prevalence of cefprozil-resistant members of the family Enterobacteriaceae (other than E. coli) in the periurethral site (P = 0.038) and of cephalothin-resistant strains of the Enterobacteriaceae in the periurethral (P = 0.005) and vaginal (P = 0.005) sites increased, but there was no significant change in the prevalence of strains of the Enterobacteriaceae in the rectal flora. In the cefaclor group, no significant change occurred in the susceptibility patterns of E. coli and of other members of the Enterobacteriaceae in these sites. The diverse effect of cefprozil versus cefaclor on the urogenital flora might be partly explained by the pharmacokinetic properties of these drugs. Cefaclor is absorbed (75 to 95%) rapidly from the intestine and excreted mainly in the urine within 2 h of oral dosing (2, 3, 25) . Cefprozil is absorbed (66%) at a lower rate than cefaclor, allowing effective drug levels in plasma and urine for up to 8 h after oral dosing (1-3, 22, 25) . It is likely that the longer exposure of the urogenital sites to the drug in the cefprozil group partly accounts for the more extensive changes in the frequency of bacterial colonization and bacterial susceptibility patterns. The effects of cefaclor on the urogenital and rectal flora described here are in agreement with previous reports (9, 15, 21) .
Both drugs were well tolerated by 85 and 92% of the patients, respectively (P, not significant). A total of 25 patients (35%) in the cefprozil group experienced at least one adverse event during therapy; of these, 3 (4%) had pruritic rash, 2 (3%) had nausea and vomiting, 2 (3%) had dizziness, and 1 (1%) had diarrhea. Three patients (4%) discontinued therapy, two because of nausea and vomiting and one because of a pruritic rash.
Nine patients (25%) in the cefaclor group reported at least one adverse event. Of these, two (6%) developed itching eyes (one with swollen eyelids) and one (3%) experienced vaginal spotting. Adverse events were mostly mild to moderate, transient, and consistent with those reported for cephalosporin (7, 12, 13, 15, 17, 18) .
Candida vaginitis was experienced by 22% of the cefprozil and cefaclor patients at 5 to 9 days posttherapy, consistent with results reported for beta-lactam antibiotics (11) . Post 
